{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:50:39Z","timestamp":1772941839488,"version":"3.50.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:00:00Z","timestamp":1795046400000},"content-version":"am","delay-in-days":291,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"publisher","award":["RO1AA029398"],"award-info":[{"award-number":["RO1AA029398"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"publisher","award":["R21AA031293"],"award-info":[{"award-number":["R21AA031293"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01CX002472"],"award-info":[{"award-number":["I01CX002472"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cld.2025.08.008","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:31:44Z","timestamp":1759541504000},"page":"107-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease Modulating Agents in Cirrhosis"],"prefix":"10.1016","volume":"30","author":[{"given":"Vinay","family":"Jahagirdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmohan Singh","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.cld.2025.08.008_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153340","article-title":"Serum biomarkers of liver fibrosis staging in the era of the concept \"compensated advanced chronic liver disease\"","volume":"10","author":"Fujita","year":"2021","journal-title":"J Clin Med"},{"issue":"10308","key":"10.1016\/j.cld.2025.08.008_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.cld.2025.08.008_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14309\/ajg.0000000000001595","article-title":"Acute-on-chronic liver failure clinical guidelines","volume":"117","author":"Bajaj","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The Baveno VII concept of cirrhosis recompensation","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.14309\/ajg.0000000000002953","article-title":"The Liver Cirrhosis Network Cohort Study: cirrhosis definition, study population, and endpoints","volume":"120","author":"Tapper","year":"2025","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"issue":"9","key":"10.1016\/j.cld.2025.08.008_bib9","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/MCG.0000000000000162","article-title":"Cirrhosis regression in patients with viral hepatitis B and C: a systematic review","volume":"48","author":"Manne","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMra1504367","article-title":"Treatment of patients with cirrhosis","volume":"375","author":"Ge","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.17380","article-title":"Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis","volume":"57","author":"Gillespie","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","volume":"43","author":"Turco","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.08.008_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7932046","article-title":"Carvedilol Inhibits Angiotensin II-induced proliferation and contraction in hepatic stellate cells through the RhoA\/Rho-Kinase Pathway","volume":"2019","author":"Wu","year":"2019","journal-title":"BioMed Res Int"},{"issue":"8187","key":"10.1016\/j.cld.2025.08.008_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol--a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/hep.30220","article-title":"Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis","volume":"69","author":"Sharma","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib18","first-page":"Cd004544","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","volume":"2012","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.cld.2025.08.008_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/apt.14485","article-title":"Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding","volume":"47","author":"Pfisterer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2004.05.004","article-title":"A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis","volume":"127","author":"Merkel","year":"2004","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.cld.2025.08.008_bib21","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed#","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib23","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/hep.30220","article-title":"Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis","volume":"69","author":"Sharma","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/gut.2009.192039","article-title":"Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial","volume":"59","author":"Mishra","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cgh.2013.07.015","article-title":"Management of gastric varices","volume":"12","author":"Garcia-Pag\u00e1n","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cgh.2024.03.046","article-title":"AGA clinical practice update on management of iron deficiency anemia: expert review","volume":"22","author":"DeLoughery","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8755","key":"10.1016\/j.cld.2025.08.008_bib27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0140-6736(91)93125-S","article-title":"Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis","volume":"337","author":"P\u00e9rez-Ayuso","year":"1991","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1067\/mge.2001.114062","article-title":"The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial","volume":"53","author":"Lo","year":"2001","journal-title":"Gastrointest Endosc"},{"issue":"10181","key":"10.1016\/j.cld.2025.08.008_bib29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HEP.0000000000000342","article-title":"Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: a Bayesian reanalysis of the PREDESCI trial","volume":"78","author":"Rowe","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib31","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/hep.1840360612","article-title":"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis","volume":"36","author":"Ba\u00f1ares","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.32737","article-title":"Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study","volume":"77","author":"Serper","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12072-019-09986-9","article-title":"Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial","volume":"13","author":"Kumar","year":"2019","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib35","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.cgh.2021.07.012","article-title":"Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death","volume":"20","author":"Jachs","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.08.008_bib36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/apt.18261","article-title":"Impact of non-selective beta blockers on further decompensation and death in decompensated cirrhosis: benefit and risk stratification by MELD score","volume":"60","author":"Wang","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.08.008_bib37","series-title":"Beta blockers, in StatPearls. 2025, StatPearls Publishing Copyright \u00a9","author":"Farzam","year":"2025"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMra1504367","article-title":"Treatment of patients with cirrhosis","volume":"375","author":"Ge","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jhep.2020.05.011","article-title":"Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites","volume":"73","author":"T\u00e9llez","year":"2020","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib40","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","article-title":"Nonselective \u03b2-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis","volume":"14","author":"Chirapongsathorn","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.15439","article-title":"Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis","volume":"50","author":"Tergast","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib42","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2025.08.008_bib43","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.cgh.2022.08.033","article-title":"AGA clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: expert review","volume":"20","author":"Flamm","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.08.008_bib44","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2025.08.008_bib45","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/liv.13119","article-title":"Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers","volume":"36","author":"Bang","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib46","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/apt.16156","article-title":"Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection","volume":"53","author":"Sasso","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib47","first-page":"Cd013121","article-title":"Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis","volume":"4","author":"Roccarina","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.288.3.351","article-title":"Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction","volume":"288","author":"Ko","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2007.01191.x","article-title":"Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis","volume":"102","author":"Albillos","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2025.08.008_bib50","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.cld.2025.08.008_bib51","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1572-0241.2007.01481.x","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"102","author":"Garcia-Tsao","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib52","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib53","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2023.13147","article-title":"Albumin, an interesting and functionally diverse protein, varies from \u2018native\u201d to \u2018effective\u2019","volume":"29","author":"Wu","year":"2024","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1748-1716.2008.01893.x","article-title":"Determination of the charge of the plasma proteins and consequent Donnan equilibrium across the capillary barriers in the rat microvasculature","volume":"194","author":"R\u00fcgheimer","year":"2008","journal-title":"Acta Physiol"},{"issue":"18","key":"10.1016\/j.cld.2025.08.008_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810086","article-title":"Serum albumin: a multifaced enzyme","volume":"22","author":"De Simone","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.cld.2025.08.008_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM196703022760903","article-title":"Hemodynamics in the cirrhotic patient during paracentesis","volume":"276","author":"Knauer","year":"1967","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hep.1840070302","article-title":"Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function","volume":"7","author":"Simon","year":"1987","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib58","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/hep.31071","article-title":"Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure","volume":"72","author":"Arora","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib59","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.gastro.2023.10.016","article-title":"AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review","volume":"166","author":"Garcia-Tsao","year":"2024","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.cld.2025.08.008_bib61","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMra2021808","article-title":"The evolving challenge of infections in cirrhosis","volume":"384","author":"Bajaj","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib62","doi-asserted-by":"crossref","DOI":"10.1186\/cc10462","article-title":"Effects of changes in arterial pressure on organ perfusion during septic shock","volume":"15","author":"Thooft","year":"2011","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"issue":"10s","key":"10.1016\/j.cld.2025.08.008_bib64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cgh.2023.04.034","article-title":"Pathophysiology of hepatorenal syndrome - acute kidney injury","volume":"21","author":"Adebayo","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMra2215289","article-title":"Acute kidney injury in patients with cirrhosis","volume":"388","author":"Nadim","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib66","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.08.008_bib67","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/CCM.0000000000005595","article-title":"The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis","volume":"50","author":"Pitre","year":"2022","journal-title":"Crit Care Med"},{"issue":"10138","key":"10.1016\/j.cld.2025.08.008_bib68","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib70","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sola","year":"2018","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.08.008_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023754","article-title":"ATTIRE: albumin to prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial","volume":"8","author":"China","year":"2018","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib72","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","article-title":"Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study","volume":"59","author":"Sim\u00f3n-Talero","year":"2013","journal-title":"J Hepatol"},{"issue":"21","key":"10.1016\/j.cld.2025.08.008_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214885","article-title":"Effects of albumin on survival after a hepatic encephalopathy episode: randomized double-blind trial and meta-analysis","volume":"10","author":"Ventura-Cots","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.09.009","article-title":"A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study","volume":"78","author":"Fagan","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib76","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/hep.31836","article-title":"Albumin in advanced liver diseases: the good and bad of a drug","volume":"74","author":"Jagdish","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib77","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2014.11.017","article-title":"Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial","volume":"62","author":"Thevenot","year":"2015","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.08.008_bib78","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s12630-021-01991-7","article-title":"Albumin in adult cardiac surgery: a narrative review","volume":"68","author":"Hanley","year":"2021","journal-title":"Can J Anaesth"},{"issue":"7","key":"10.1016\/j.cld.2025.08.008_bib79","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/eri.10.58","article-title":"Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections","volume":"8","author":"Cottreau","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.08.008_bib80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"Bajaj","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib81","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jhep.2013.01.038","article-title":"Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function","volume":"58","author":"Du Plessis","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.08.008_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116845","article-title":"Therapeutic potential and mechanisms of Rifaximin in ameliorating iron overload-induced ferroptosis and liver fibrosis in vivo and in vitro","volume":"484","author":"Yuan","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib83","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2468-1253(23)00010-9","article-title":"Rifaximin-\u03b1 for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.08.008_bib84","first-page":"Cd011585","article-title":"Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"7","author":"Zacharias","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib85","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039905","article-title":"Efficacy and safety of rifaximin for the prophylaxis of hepatic encephalopathy: a meta-analysis","volume":"104","author":"Huang","year":"2025","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib86","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.08.008_bib87","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib88","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000443361","article-title":"The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin","volume":"34","author":"Ponziani","year":"2016","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib89","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/gutjnl-2020-322470","article-title":"Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy","volume":"70","author":"Bajaj","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib91","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial","volume":"76","author":"Patel","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2025.08.008_bib92","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/MEG.0000000000000743","article-title":"Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival","volume":"28","author":"Hanafy","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3748\/wjg.v26.i2.199","article-title":"Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study","volume":"26","author":"Lv","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2025.08.008_bib94","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.14275","article-title":"Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy","volume":"46","author":"Kang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.08.008_bib95","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818800307","article-title":"Rifaximin has the potential to prevent complications of cirrhosis","volume":"11","author":"Flamm","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.08.008_bib96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/apt.15326","article-title":"Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list","volume":"50","author":"Salehi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.cld.2025.08.008_bib97","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/MEG.0000000000000724","article-title":"Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis","volume":"28","author":"Elfert","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib98","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","article-title":"Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study","volume":"10","author":"Assem","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2025.08.008_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.06.019","article-title":"Effect of rifaximin in patients with severe cirrhosis and ascites: a randomized double-blind placebo-controlled clinical trial","author":"Th\u00e9venot","year":"2025","journal-title":"J Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.cld.2025.08.008_bib100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/apt.14361","article-title":"Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis","volume":"46","author":"Goel","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.cld.2025.08.008_bib101","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MEG.0000000000000940","article-title":"Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis","volume":"29","author":"Kamal","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8040","key":"10.1016\/j.cld.2025.08.008_bib102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41586-024-08095-4","article-title":"Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin","volume":"635","author":"Turner","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib103","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.gastro.2025.03.014","article-title":"Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two national US-Based Cohorts","volume":"169","author":"Silvey","year":"2025","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2025.08.008_bib104","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cgh.2022.05.042","article-title":"Dosing of rifaximin soluble solid dispersion tablets in adults with cirrhosis: 2 randomized, placebo-controlled trials","volume":"21","author":"Bajaj","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.08.008_bib106","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib107","doi-asserted-by":"crossref","first-page":"G147","DOI":"10.1152\/ajpgi.00462.2007","article-title":"Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver","volume":"296","author":"Moreno","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib108","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.08.008_bib109","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis c-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7326\/M18-2753","article-title":"Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a Nationwide Swedish Population","volume":"171","author":"Simon","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib111","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","article-title":"Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort","volume":"76","author":"Mahmud","year":"2022","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.08.008_bib112","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib113","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.08.008_bib115","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and rifaximin in decompensated cirrhosis: a randomized clinical trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cld.2025.08.008_bib116","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial","volume":"7","author":"Kronborg","year":"2023","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.cld.2025.08.008_bib117","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.08.008_bib118","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12876-021-01704-w","article-title":"A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis","volume":"21","author":"Sung","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"28","key":"10.1016\/j.cld.2025.08.008_bib119","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.3748\/wjg.v27.i28.4639","article-title":"Addition of statins to the standard treatment in patients with cirrhosis: safety and efficacy","volume":"27","author":"Mu\u00f1oz","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"24","key":"10.1016\/j.cld.2025.08.008_bib120","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cld.2025.08.008_bib121","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:18:42Z","timestamp":1772882322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1089326125000819"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.08.008","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease Modulating Agents in Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}